Cargando…

Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment

Aggressive pelvic angiomyxoma is a very rare mesenchymal tumor that is usually diagnosed in premenopausal female patients. The current mainly reported treatment is wide surgical excision. Other treatment options, such as radiotherapy and hormonal therapy, have been suggested as potential alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajjar, Roy, Alharthi, Mohammed, Richard, Carole, Gougeon, François, Loungnarath, Rasmy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559397/
https://www.ncbi.nlm.nih.gov/pubmed/31245206
http://dx.doi.org/10.7759/cureus.4419
_version_ 1783425822173954048
author Hajjar, Roy
Alharthi, Mohammed
Richard, Carole
Gougeon, François
Loungnarath, Rasmy
author_facet Hajjar, Roy
Alharthi, Mohammed
Richard, Carole
Gougeon, François
Loungnarath, Rasmy
author_sort Hajjar, Roy
collection PubMed
description Aggressive pelvic angiomyxoma is a very rare mesenchymal tumor that is usually diagnosed in premenopausal female patients. The current mainly reported treatment is wide surgical excision. Other treatment options, such as radiotherapy and hormonal therapy, have been suggested as potential alternatives. A 61-year-old postmenopausal female patient presented with hematuria that led to the identification of a perirectal mass on abdominopelvic imaging. A 46-year-old female patient presented with a perineal mass of unknown etiology. Despite extensive investigations, the diagnosis could not be confirmed before surgical resection in both patients. Surgical excisions were performed and revealed the presence of an aggressive angiomyxoma with positive estrogen and progesterone tumoral receptors in both cases. Radiological and clinical recurrence was noted in one patient. Tumor regression was noted in this patient after treatment with a luteinizing hormone-releasing hormone (LHRH) agonist with long-term remission. The diagnosis of a perirectal aggressive angiomyxoma is an exceedingly rare event. Preoperative biopsy and pathological diagnosis are challenging and often yields poor results. Its slow growth and expression of hormonal receptors make noninvasive therapeutic strategies, such as radiotherapy, gonadotropin-releasing hormone agonists, or even watchful waiting, valid options in selected patients. Due to the lack of reported cases, the best treatment has yet to be elucidated.
format Online
Article
Text
id pubmed-6559397
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-65593972019-06-26 Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment Hajjar, Roy Alharthi, Mohammed Richard, Carole Gougeon, François Loungnarath, Rasmy Cureus Obstetrics/Gynecology Aggressive pelvic angiomyxoma is a very rare mesenchymal tumor that is usually diagnosed in premenopausal female patients. The current mainly reported treatment is wide surgical excision. Other treatment options, such as radiotherapy and hormonal therapy, have been suggested as potential alternatives. A 61-year-old postmenopausal female patient presented with hematuria that led to the identification of a perirectal mass on abdominopelvic imaging. A 46-year-old female patient presented with a perineal mass of unknown etiology. Despite extensive investigations, the diagnosis could not be confirmed before surgical resection in both patients. Surgical excisions were performed and revealed the presence of an aggressive angiomyxoma with positive estrogen and progesterone tumoral receptors in both cases. Radiological and clinical recurrence was noted in one patient. Tumor regression was noted in this patient after treatment with a luteinizing hormone-releasing hormone (LHRH) agonist with long-term remission. The diagnosis of a perirectal aggressive angiomyxoma is an exceedingly rare event. Preoperative biopsy and pathological diagnosis are challenging and often yields poor results. Its slow growth and expression of hormonal receptors make noninvasive therapeutic strategies, such as radiotherapy, gonadotropin-releasing hormone agonists, or even watchful waiting, valid options in selected patients. Due to the lack of reported cases, the best treatment has yet to be elucidated. Cureus 2019-04-09 /pmc/articles/PMC6559397/ /pubmed/31245206 http://dx.doi.org/10.7759/cureus.4419 Text en Copyright © 2019, Hajjar et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Obstetrics/Gynecology
Hajjar, Roy
Alharthi, Mohammed
Richard, Carole
Gougeon, François
Loungnarath, Rasmy
Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment
title Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment
title_full Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment
title_fullStr Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment
title_full_unstemmed Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment
title_short Pelvic Aggressive Angiomyxoma: Major Challenges in Diagnosis and Treatment
title_sort pelvic aggressive angiomyxoma: major challenges in diagnosis and treatment
topic Obstetrics/Gynecology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559397/
https://www.ncbi.nlm.nih.gov/pubmed/31245206
http://dx.doi.org/10.7759/cureus.4419
work_keys_str_mv AT hajjarroy pelvicaggressiveangiomyxomamajorchallengesindiagnosisandtreatment
AT alharthimohammed pelvicaggressiveangiomyxomamajorchallengesindiagnosisandtreatment
AT richardcarole pelvicaggressiveangiomyxomamajorchallengesindiagnosisandtreatment
AT gougeonfrancois pelvicaggressiveangiomyxomamajorchallengesindiagnosisandtreatment
AT loungnarathrasmy pelvicaggressiveangiomyxomamajorchallengesindiagnosisandtreatment